Skip to main content
Premium Trial:

Request an Annual Quote

Daniel O Day, Heiner Dreismann, CombiMatrix, DNA Chip Research


People in the News

Roche has tapped Daniel O'Day to head its Roche Molecular Diagnostics business.

O'Day succeeds former RMD chief Heiner Dreismann. He most recently served as head of operations for Roche Pharmaceuticals in Denmark, Roche said. The company added that during his career with Roche, O'Day has spent 11 years in commercial positions in the US and eight years in international assignments in Switzerland, Japan, and Denmark.

As head of the RMD business area, the company said O'Day will be responsible for all of RMD's global functions including research, development, manufacturing, and marketing as well as all site operations in Pleasanton and Alameda, California; Branchburg and Belleville, New Jersey; and Penzberg, Germany.

O'Day holds a BSc in biology from Georgetown University and an MBA from Columbia University.


New Product Watch

CombiMatrix this week launched upgraded versions of its CustomArray and CustomArray Synthesizer that enable users to synthesize the firm's CustomArray 90K, an array that can contain up to 94,000 features.

Michael Tognotti, CMBX's vice president of sales and marketing, said in a statement that the company will next launch a whole-human-genome array.

DNA Chip Research last month launched its AceGene Premium Human 30K microarray.

The Japanese company said that the new chip has improved the sensitivity of the existing AceGene Human 30K chip by two- to five-fold.

DNA Chip Research also said that it expects to generate 200 million yen ($1.7 million) in annual sales of the AceGene Premium series. In addition, the company said that an AceGene Premium Mouse chip will be available in April 2007.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.